Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma

H. Worth (Fürth, Germany), C. Criée (Göttingen, Germany), C. Vogelmeier (Marburg , Germany), P. Kardos (Frankfurt, Germany), E. Becker (Frankfurt, Germany), K. Kostev (Frankfurt, Germany), I. Mokros (Wedel, Germany), A. Schneider (Wedel, Germany)

Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Session: Inhaled corticosteroids and bronchodilator studies in asthma
Session type: E-poster session
Number: 2633
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Worth (Fürth, Germany), C. Criée (Göttingen, Germany), C. Vogelmeier (Marburg , Germany), P. Kardos (Frankfurt, Germany), E. Becker (Frankfurt, Germany), K. Kostev (Frankfurt, Germany), I. Mokros (Wedel, Germany), A. Schneider (Wedel, Germany). Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma. 2633

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Nighttime short-acting beta-agonist (SABA) in asthma and COPD
Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases
Year: 2019

Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019



Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020


Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013


The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care
Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease
Year: 2007


Combination therapy of inhaled corticosteroids and long-acting beta2-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking
Source: Eur Respir J 2006; 28: Suppl. 50, 454s
Year: 2006

First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004


Bronchodilator therapies for severe asthma
Source: Eur Respir Mon 2011; 51: 253-267
Year: 2011


Variability in asthma severity among steroid-naive patients previously receiving short-acting beta2-agonists
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017

Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids
Source: Eur Respir J 2016; 48: 558-560
Year: 2016


Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016
Year: 2017



Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020


Is the combination of long-acting β2-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma?
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Cough variant asthma treated with bronchodilators, without inhaled corticosteroids
Source: Annual Congress 2009 - From cough to sound analysis of breathing
Year: 2009

Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD
Source: Eur Respir J 2010; 36: 494-502
Year: 2010



The effect of inhaled corticosteroids in combination with long-acting beta2-agonists in elite athletes with asthma
Source: Annual Congress 2009 - Asthma and comorbid conditions
Year: 2009

Excess morbidity and mortality in patients with asthma on long-acting beta2-agonists
Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths
Year: 2007